Prognostic variables for patients with stage III malignant melanoma.

The European journal of surgery = Acta chirurgica Pub Date : 2000-03-01 DOI:10.1080/110241500750009348

G E Messaris, M M Konstadoulakis, N Ricaniadis, E Leandros, G Androulakis, P C Karakousis

{"title":"Prognostic variables for patients with stage III malignant melanoma.","authors":"G E Messaris, M M Konstadoulakis, N Ricaniadis, E Leandros, G Androulakis, P C Karakousis","doi":"10.1080/110241500750009348","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.Design: Retrospective study.Setting: Specialist hospital, USA.Subjects: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.Main outcome measures: Survival and prognostic factors on multivariate analysis.Results: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004).Conclusion: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.","PeriodicalId":22411,"journal":{"name":"The European journal of surgery = Acta chirurgica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/110241500750009348","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European journal of surgery = Acta chirurgica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/110241500750009348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

Objective: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.

Design: Retrospective study.

Setting: Specialist hospital, USA.

Subjects: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.

Main outcome measures: Survival and prognostic factors on multivariate analysis.

Results: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004).

Conclusion: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.

查看原文本刊更多论文

III期恶性黑色素瘤患者的预后变量。

目的:评估III期恶性黑色素瘤患者的预后因素，并确定可能从辅助治疗中获益的复发性疾病高风险患者。设计:回顾性研究。地点:美国专科医院。研究对象:1970年至1992年间在罗斯威尔公园癌症研究所接受治疗的130例III期恶性黑色素瘤患者(根据TNM分类)。主要结局指标:多变量分析的生存和预后因素。结果:4个因素是III期恶性黑色素瘤患者的独立预后指标:年龄>51岁(p = 0.008)， >3个受累淋巴结(p = 0.03)，原发肿瘤在头部或躯干的位置(p = 0.007)，有无可触及淋巴结(p = 0.004)。结论:这些预后因素有助于我们将患者分为低危组和高危组。在未来的黑色素瘤治疗试验中，高风险患者可能受益于更积极的辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The European journal of surgery = Acta chirurgica

自引率

0.00%

发文量

文献相关原料

公司名称	产品信息	采购帮参考价格